Drug intelligence / Profile preview

[18F]-LY3818850

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**[18F]-LY3818850** is a radiolabeled investigational **positron emission tomography (PET) tracer** used to measure **brain receptor occupancy** for the drug LY3857210 in clinical research settings. Its primary scientific role is as a radioligand for PET imaging of the central nervous system, specifically to detect LY3857210 binding to its target receptor in the brain. The compound incorporates fluorine-18 ([18F]), a radioactive isotope widely used in PET imaging. The developer of [18F]-LY3818850 is Eli Lilly and Company, and it has primarily been used to facilitate basic science research rather than direct therapeutic intervention[1][3][4][9].

Brand names: [18F]-LY3818850
Other names: [18F]-LY3818850

Beyond the preview

Go deeper on [18F]-LY3818850.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]-LY3818850.

Explore the full profile